# beyond abstract (audio feeds) — RSS Amplifier Recent posts from the 1 feeds in the RSS Amplifier directory that cover beyond abstract. Page: Feed: --- ## [PSMAddition: Does Earlier Really Mean Better?](https://beyondtheabstracturology.substack.com/p/psmaddition-does-earlier-really-mean) _2026-08-03 · Dries Develtere · Beyond The Abstract: Urology_ The Drug Is Ready for the Clinic. The Manuscript Is Still Missing. ## [PROTEUS trial](https://beyondtheabstracturology.substack.com/p/proteus-trial) _2026-07-07 · Dries Develtere · Beyond The Abstract: Urology_ A trial that raises more questions than it answers. ## [Metformin and Prostate Cancer: The Tale Continues](https://beyondtheabstracturology.substack.com/p/metformin-and-prostate-cancer-the) _2026-05-18 · Dries Develtere · Beyond The Abstract: Urology_ From observational promise to consistent negative randomized evidence ## [Beyond the Abstract: EV-303 (KEYNOTE-905)](https://beyondtheabstracturology.substack.com/p/beyond-the-abstract-ev-303-keynote) _2026-04-25 · Dries Develtere · Beyond The Abstract: Urology_ Practice-changing results — but there is a problem after progression ## [PEACE-3 — Does Earlier Radium-223 Actually Matter?](https://beyondtheabstracturology.substack.com/p/peace-3-does-earlier-radium-223-actually) _2026-03-23 · Dries Develtere · Beyond The Abstract: Urology_ Post-progression therapy suggests limited use of radium-223 in the control arm ## [Oxybutynin to treat Hot Flushes in Prostate Cancer](https://beyondtheabstracturology.substack.com/p/oxybutynin-to-treat-hot-flushes-in) _2026-02-11 · Dries Develtere · Beyond The Abstract: Urology_ Cooling the Heat Without Heating the Budget ## [Ultra-hypofractinated radiotherapy in prostate cancer](https://beyondtheabstracturology.substack.com/p/ultra-hypofractinated-radiotherapy) _2026-02-10 · Dries Develtere · Beyond The Abstract: Urology_ Prospective 10-Year Radiotherapy Data Show Higher-Than-Expected Toxicity—And We Still Await the Patient Voice ## [PSA for Prostate Cancer Screening: How ERSPC confirms the importance of active surveillance](https://beyondtheabstracturology.substack.com/p/psa-for-prostate-cancer-screening) _2026-01-27 · Dries Develtere · Beyond The Abstract: Urology_ Interpreting the 23 year ERSPC results in the era of MRI, risk stratification, and active surveillance ## [IMvigor011: A Biology-Guided Approach to Adjuvant Immunotherapy](https://beyondtheabstracturology.substack.com/p/imvigor011-a-biology-guided-approach) _2026-01-22 · Dries Develtere · Beyond The Abstract: Urology_ Solid trial, but don't call it "adjuvant" ## [IO & Prostate cancer: When Two Phase III Trials Answer the Same Question—and the Answer Is “No”](https://beyondtheabstracturology.substack.com/p/io-and-prostate-cancer-when-two-phase) _2026-01-15 · Dries Develtere · Beyond The Abstract: Urology_ Spoiler alert: no room for checkpoint inhibitors in metastatic prostate cancer! ## [Stop CI/CD & Supply-Chain Attacks (Sponsored)](https://crawlproof.com/a/wy1F1UMIGHPL) _2026-01-15 · **Sponsored**_ Per-PR: 17 CI/CD checks and package malware scans with inline Check Run findings. ## [TALAPRO-2: a strong trial, a real survival gain, but at the cost of high toxicity](https://beyondtheabstracturology.substack.com/p/talapro-2-a-strong-trial-a-real-survival) _2026-01-02 · Dries Develtere · Beyond The Abstract: Urology_ A strong case for intensification, without closing the sequencing debate ## [A First Year of Looking Beyond the Abstract: 2025 in Urology Trials](https://beyondtheabstracturology.substack.com/p/a-first-year-of-looking-beyond-the) _2026-01-01 · Dries Develtere · Beyond The Abstract: Urology_ Looking back at 2025, one pattern stands out: a year full of anticipation, but light on true game-changers. ## [CREST Trial: Positivity by Redesign, Ethical Concerns in Treatment Allocation, and Industry-Controlled Safety Signals](https://beyondtheabstracturology.substack.com/p/crest-trial-positivity-by-redesign) _2025-12-10 · Dries Develtere · Beyond The Abstract: Urology_ Another "Game Changer" with major limitations ## [CAPItello-281 phase III study: Not a Game Changer at all in prostate cancer treatment](https://beyondtheabstracturology.substack.com/p/capitello-281-phase-iii-study-not) _2025-12-04 · Dries Develtere · Beyond The Abstract: Urology_ A closer look at why capivasertib fails to deliver meaningful benefit in PTEN-deficient mHSPC ## [SEXTANT-PRO: A Clean Non-Inferiority Trial With Practice-Changing Potential](https://beyondtheabstracturology.substack.com/p/sextant-pro-a-clean-non-inferiority) _2025-11-29 · Dries Develtere · Beyond The Abstract: Urology_ In MRI-positive patients, accuracy may not come from more sampling — but from smarter sampling. ## [Metformin in Active Surveillance: A Simple Question, a Clear Answer](https://beyondtheabstracturology.substack.com/p/metformin-in-active-surveillance) _2025-11-08 · Dries Develtere · Beyond The Abstract: Urology_ Spoiler alert: negative results are also results, which lead to progress ## [Urothelial Cancer Breakthrough: Beyond the RC48-C016 Abstract](https://beyondtheabstracturology.substack.com/p/urothelial-cancer-breakthrough-beyond) _2025-11-05 · Dries Develtere · Beyond The Abstract: Urology_ Disitamab Vedotin + Toripalimab in HER2-Expressing Advanced Urothelial Cancer - New England Journal of Medicine, October 2025 ## [The AMPLITUDE Trial — PARP Inhibition Moves Upstream in HRR-Deficient mCSPC](https://beyondtheabstracturology.substack.com/p/the-amplitude-trial-parp-inhibition) _2025-10-28 · Dries Develtere · Beyond The Abstract: Urology_ Johnson & Johnson want Niraparib in the hormone-sensitive BRCA-altered prostate cancer setting based on PFS — efficacy signal, but fundamental design flaws remain. ## [EMBARK Final Results: OS benefit with a catch](https://beyondtheabstracturology.substack.com/p/embark-final-results-os-benefit-with) _2025-10-20 · Dries Develtere · Beyond The Abstract: Urology_ Do we have enough data to defend the use of Enzalutamide in the Biochemical Recurrence setting? ## [8.1% APY Plus Free Stock (Sponsored)](https://crawlproof.com/a/6rNbBUSUa8dC) _2025-10-20 · **Sponsored**_ Claim 8.1% APY and up to $1,030 in SK hynix and Nvidia stock. ## [POTOMAC: A Closer Look at Durvalumab in BCG-Naive NMIBC](https://beyondtheabstracturology.substack.com/p/potomac-a-closer-look-at-durvalumab) _2025-10-18 · Dries Develtere · Beyond The Abstract: Urology_ The POTOMAC trial results are out — presented at ESMO and now published in The Lancet.